We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+10.34%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$5.32B
AUM Growth
+$623M
(+13%)
Cap. Flow
+$473M
Cap. Flow
% of AUM
8.88%
Top 10 Holdings %
Top 10 Hldgs %
31.02%
Holding
1,563
New
308
Increased
332
Reduced
859
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Equinix
EQIX
|
+$43.7M |
| 2 |
American Tower
AMT
|
+$34.7M |
| 3 |
Crown Castle
CCI
|
+$21.3M |
| 4 |
CD
Chindata Group Holdings Limited American Depositary Shares
CD
|
+$19.1M |
| 5 |
CONE
CyrusOne Inc Common Stock
CONE
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$80.9M |
| 2 |
Microsoft
MSFT
|
+$63.9M |
| 3 |
Amazon
AMZN
|
+$61.8M |
| 4 |
Meta Platforms (Facebook)
META
|
+$26.4M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$24.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.33% |
| 2 | Technology | 16.44% |
| 3 | Consumer Discretionary | 8.8% |
| 4 | Healthcare | 7.69% |
| 5 | Communication Services | 7.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1201
BioCryst Pharmaceuticals
BCRX
$2.44B
| $119K | ﹤0.01% |
15,945
-8,558
| -35% | -$44.1K |
|
|
ZEUS
1202
DELISTED
Olympic Steel
ZEUS
| $119K | ﹤0.01% |
8,934
-2,275
| -20% | -$30.6K |
|
1203
Akebia Therapeutics
AKBA
$338M
| $117K | ﹤0.01% |
41,750
+37,032
| +785% | +$108K |
|
1204
Cytokinetics
CYTK
$10.7B
| $117K | ﹤0.01% |
5,631
+3,234
| +135% | +$59.1K |
|
1205
Novavax
NVAX
$1.21B
| $117K | ﹤0.01% |
1,046
-1,260
| -55% | -$134K |
|
1206
Opko Health
OPK
$1.06B
| $117K | ﹤0.01% |
29,738
-12,650
| -30% | -$52.8K |
|
1207
Vir Biotechnology
VIR
$1.46B
| $117K | ﹤0.01% |
4,378
+4,206
| +2,445% | +$137K |
|
|
SRNE
1208
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $117K | ﹤0.01% |
17,210
+3,904
| +29% | +$31.4K |
|
1209
American Public Education
APEI
$943M
| $115K | ﹤0.01% |
3,779
+1,103
| +41% | +$33.9K |
|
1210
Thomson Reuters
TRI
$46.2B
| $115K | ﹤0.01% |
+1,330
| New | +$114K |
|
1211
Pilgrim's Pride
PPC
$6.99B
| $114K | ﹤0.01% |
5,808
-6,748
| -54% | -$122K |
|
1212
Western Midstream Partners
WES
$19.5B
| $114K | ﹤0.01% |
8,253
-1,819
| -18% | -$20.9K |
|
|
MRSN
1213
DELISTED
Mersana Therapeutics
MRSN
| $113K | ﹤0.01% |
170
+118
| +227% | +$65.6K |
|
1214
Fastly Inc
FSLY
$3.19B
| $112K | ﹤0.01% |
+1,277
| New | +$113K |
|
1215
Immunovant
IMVT
$7.89B
| $111K | ﹤0.01% |
+2,410
| New | +$111K |
|
|
VBIV
1216
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $111K | ﹤0.01% |
+1,342
| New | +$114K |
|
|
ESPR
1217
DELISTED
Esperion Therapeutics
ESPR
| $110K | ﹤0.01% |
4,236
+1,820
| +75% | +$54.5K |
|
1218
Insmed
INSM
$22.5B
| $110K | ﹤0.01% |
3,318
-548
| -14% | -$20K |
|
1219
Madrigal Pharmaceuticals
MDGL
$12.5B
| $110K | ﹤0.01% |
986
+150
| +18% | +$18.3K |
|
|
CLDR
1220
DELISTED
Cloudera, Inc.
CLDR
| $110K | ﹤0.01% |
7,900
-1,094
| -12% | -$12.5K |
|
|
TWOU
1221
DELISTED
2U Inc
TWOU
| $109K | ﹤0.01% |
91
+3
| +3% | +$3.22K |
|
1222
Veracyte
VCYT
$4.42B
| $108K | ﹤0.01% |
2,208
-172
| -7% | -$7.97K |
|
1223
Ironwood Pharmaceuticals
IRWD
$598M
| $107K | ﹤0.01% |
9,395
-332
| -3% | -$3.63K |
|
1224
Inovio Pharmaceuticals
INO
$84.7M
| $106K | ﹤0.01% |
997
+324
| +48% | +$43.1K |
|
|
CNH
1225
CNH Industrial
CNH
$13.5B
| $106K | ﹤0.01% |
+9,462
| New | +$82.3K |
|
Similar funds
SAM
Pacer Advisors's Q4 2020 Portfolio in Review
As of Q4 2020, Pacer Advisors held 1,563 positions worth $5.32B, up 13% from $4.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Pacer Advisors deployed $473M of net new capital in Q4 2020, opening 308 new positions and adding to 332 existing holdings. Its largest new stake was Chindata Group Holdings Limited American Depositary Shares: 1,166,530 shares worth $27.9M.
By sector, the portfolio is most concentrated in Real Estate at 18% of assets, up from 17% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $80.9M trimmed.
- Pacer Advisors's largest Q4 2020 buy was Chindata Group Holdings Limited American Depositary Shares: 1,166,530 shares worth $27.9M.
- Pacer Advisors added most to Equinix in Q4 2020, an estimated $43.7M increase.
- Pacer Advisors's biggest Q4 2020 reduction was Apple, cutting an estimated $80.9M.
- Pacer Advisors fully exited INDUS Realty Trust, Inc. (MD) Common Stock in Q4 2020, selling an estimated $1.83M.
- Pacer Advisors's ten largest holdings make up 31% of its $5.32B portfolio in Q4 2020.
- Pacer Advisors opened 308 new positions and closed 60 in Q4 2020.
- Pacer Advisors's portfolio value rose 13% quarter-over-quarter to $5.32B.
Based on Pacer Advisors's 13F filing for Q4 2020, filed 20 Jan 2021.